Table 2.
Model inputs for the base-case scenario. Also shown are ranges used for the probabilistic sensitivity analysis
| Parameter | Base case value | Sensitivity analysis range | References |
|---|---|---|---|
| Discontinuation and switch | |||
| Treatment discontinuation | |||
| Without AEs | 6.4 % per month | 3.0–14.5 % | Base case and upper limit: Wagg et al. [21]; Sánchez-Ballester et al. [22]; lower limit: assumption |
| With AEs | 90 % per month | 50–100 % | Expert opinion |
| Treatment switcha | 26.1 % | 15.3–50.0 % | Base case: Odeyemi et al. [23]; sensitivity analysis: D’Souza et al. [38]/assumption |
| Treatment restartb | 5.6 % per month | 0–20.0 % | Expert opinion |
| BTX injection | 0.01 % per month | 0–0.05 % | Expert opinion |
| Success with BTX | 79 % | 50–100 % | Wu et al. [24] |
| Adverse events | |||
| Dry mouth | |||
| Mirabegron 50 mg | 2.8 % | 2.1–3.5 % | SCORPIO [15] |
| Tolterodine ER 4 mg | 10.1 % | 8.7–11.5 % | SCORPIO [15] |
| Constipation | |||
| Mirabegron 50 mg | 1.6 % | SCORPIO [15] | |
| Tolterodine ER 4 mg | 2.0 % | SCORPIO [15] | |
AE adverse event, BTX botulinum toxin, ER extended release, OAB overactive bladder syndrome
a Among patients discontinuing OAB treatment
b Split between different medications was assumed to be one-third each for initial, second- and third-line treatments